

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

INSIDE INFORMATION

ASCLETIS ANNOUNCES COOPERATION WITH CHINA MEHECO INTERNATIONAL CO., LTD. IN DISTRIBUTION OF ITS RITONAVIR TABLETS IN CHINESE MAINLAND

This announcement is made by Ascletis Pharma Inc. (the “**Company**” or “**Ascletis**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that Ascletis Pharmaceuticals Co., Ltd. (歌禮藥業(浙江)有限公司, “**Ascletis Pharmaceuticals**”) has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavir tablets in Chinese mainland. Ascletis Pharmaceuticals is a wholly-owned subsidiary of the Company, and China Meheco International Co., Ltd. is a wholly-owned subsidiary of China Meheco Group Co., Ltd. (“**China Meheco**”, stock code in Shanghai Stock Exchange: 600056).

Ritonavir tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases. Ascletis owns the only authorized ritonavir tablet in China, which has passed bioequivalence study. Ascletis’ ritonavir tablet was approved in September 2021 by China National Medical Products Administration (國藥准字 H20213698).

Ascletis has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) in 12 European countries (Germany, France, Ireland, the United Kingdom, Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark) and Hong Kong, China.

Yadong Li, Chairman and Secretary of the Party Committee of China Meheco, said, “As the national team in the medical industry in China, China Meheco committed to its original mission of ‘safeguarding people’s health’. By this opportunity, we hope to explore various levels of cooperation with biotech companies in China such as Ascletis. Together, we contribute to ‘Healthy China 2030’.”

Dr. Jinzi J. Wu, Founder, Chairman of the Board and CEO of Ascletis, said, “It’s a great honor to cooperate with China Meheco in commercialization of ritonavir tablets. China Meheco, as a leading distributor of pharmaceuticals in China, boasts nationwide sales network of antiviral drugs. Ascletis’ ritonavir tablet, one of the marketed products of our antiviral pipeline, is the only authorized ritonavir tablet in China that has passed bioequivalence study. We are looking forward to the cooperation with China Meheco. With Ascletis’ product and China Meheco’s network, we will shoulder the social responsibilities of eliminating infectious diseases.”

All-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/GANOVO® (Danoprevir) regimen is Ascletis’ another marketed antiviral product, included in *the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021)* (《國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)》).

Ascletis’ antiviral pipelines also include drug candidates for functional cure of Chronic Hepatitis B (CHB) and AIDS.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain the final market approvals for ritonavir in countries/areas outside Chinese mainland successfully.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People’s Republic of China
April 13, 2022

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.